RTP Mobile Logo
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer (Webinar Audio Proceedings)
Released April 2022

Featuring perspectives from Drs Emmanuel Antonarakis and Daniel Petrylak. Published April 27, 2022. (Webinar Audio Proceedings)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of prostate cancer.

    LEARNING OBJECTIVES

    • Appraise published research findings with and current guideline recommendations on optimal management approaches to biochemical recurrence following local treatment for prostate cancer, and counsel appropriate patients about the benefits of systemic therapy.
    • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the discussion of nonresearch treatment options.
    • Explore available data with the use of cytotoxic and secondary hormonal therapy to design effective treatment plans for metastatic hormone-sensitive prostate cancer.
    • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for metastatic CRPC (mCRPC), considering age, comorbidities, prior therapeutic exposure and other relevant clinical and biologic factors.
    • Assess the available and emerging research database supporting the use of PARP inhibitors for mCRPC, and discern how to optimally incorporate these agents into clinical management algorithms.
    • Appreciate the Phase III data leading to FDA approval of PSMA-targeted radioligand therapy for progressive PSMA-positive mCRPC, and understand how to optimally integrate this therapy into clinical care.
    • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Emmanuel S Antonarakis, MD
    Clark Endowed Professor of Medicine
    Division of Hematology, Oncology and Transplantation
    University of Minnesota
    Minneapolis, Minnesota

    Advisory Committee: AIkido Pharma Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Curium Pharma, Exact Sciences, Foundation Medicine, Invitae, Ismar Healthcare NV, Merck, Orion Corporation, Tempus; Consulting Agreements: EcoR1 Capital LLC, KeyQuest Health; Contracted Research: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Clovis Oncology; Other: QIAGEN: licenser of technology..

    Daniel P Petrylak, MD
    Professor of Internal Medicine (Medical Oncology) and Urology
    Yale School of Medicine
    New Haven, Connecticut

    Consulting Agreements: Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc; Contracted Research: Gilead Sciences Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas and Pfizer Inc, and Exelixis Inc.

    Release date: April 2022
    Expiration date: April 2023

Acknowledge and close

Watch video
(WIFI is recommended for best performance):